Hydropic leiomyoma: a distinct variant of leiomyoma closely related to HMGA2 overexpression.
FISH
HMGA2
Histology
Hydropic leiomyoma
Pericytes
Journal
Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
19
08
2018
revised:
22
09
2018
accepted:
29
09
2018
pubmed:
8
10
2018
medline:
16
11
2019
entrez:
8
10
2018
Statut:
ppublish
Résumé
Hydropic leiomyoma (HLM) is a variant of uterine leiomyoma with characteristic features of zonal distributions of edema, increased vascularity, and tumor cells arranged in nodules or cords. Diagnostic difficulty and patient management are further complicated by a lack of studies and unknown cause of the disease. To study this tumor's nature, 24 HLM cases were selected for analysis of cytohistologic features, immunohistochemical profile (HMGA2, FH, CD34, pAKT, p16, ER, SMA, and Ki-67), and molecular alterations of HMGA2 by fluorescence in situ hybridization and MED12 mutations. HLM showed large tumor size (average 14.4 cm) and unique histology, characterized by edematous areas of tumor cells with mostly round-oval nuclei, arranged in cords and/or with perinodular growth around vessels, and increased thick-walled vessels (average 17 vessels/10× medium-power field). Immunohistochemistry revealed that 76% (18/24) of HLMs had HMGA2 overexpression, 32% (6/19) of which harbored HMGA2 rearrangement detected by fluorescence in situ hybridization. Thick-walled vessels in HLM were composed of mostly HMGA2-positive tumor cells, and HLM with HMGA2 overexpression also showed CD34-positive tumor vessel-supporting pericytes. In contrast to usual-type leiomyoma with a high frequency of MED12 mutations, no MED12 mutations were found in any HLM. HLM showed increased pAKT activity, indicating a strong contribution of AKT pathway signaling in HLM promoting tumor growth. Our findings suggest that HLM is a distinct variant of uterine smooth muscle tumor likely driven by HMGA2 overexpression.
Identifiants
pubmed: 30292626
pii: S0046-8177(18)30376-9
doi: 10.1016/j.humpath.2018.09.012
pmc: PMC6408288
mid: NIHMS1508880
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
HMGA2 Protein
0
HMGA2 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
164-172Subventions
Organisme : NICHD NIH HHS
ID : P01 HD057877
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.
Références
Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:3-12
pubmed: 26725703
Mol Cancer. 2017 Jun 7;16(1):101
pubmed: 28592321
Histopathology. 1999 Apr;34(4):378
pubmed: 10231410
Gynecol Oncol. 2001 Oct;83(1):153-7
pubmed: 11585430
J Ultrasound Med. 1994 May;13(5):416-8
pubmed: 8015054
Mod Pathol. 2014 Aug;27(8):1144-53
pubmed: 24390224
Genes Chromosomes Cancer. 2000 Jul;28(3):235-45
pubmed: 10862029
Obstet Gynecol. 1998 Oct;92(4 Pt 2):648-9
pubmed: 9764648
Am J Surg Pathol. 1992 Jan;16(1):26-32
pubmed: 1309411
Genes Chromosomes Cancer. 2018 Oct;57(10):485-494
pubmed: 29790226
Pathol Int. 2002 Aug;52(8):540-3
pubmed: 12366814
J Obstet Gynaecol Res. 2014 Apr;40(4):1137-40
pubmed: 24612300
Br J Radiol. 2009 Aug;82(980):e164-7
pubmed: 19592400
Am J Surg Pathol. 1999 Sep;23(9):1032-9
pubmed: 10478662
Science. 2011 Oct 14;334(6053):252-5
pubmed: 21868628
Hum Pathol. 1997 Feb;28(2):249-51
pubmed: 9023411
BMJ Case Rep. 2015 Sep 08;2015:
pubmed: 26351316
Indian J Pathol Microbiol. 2010 Jan-Mar;53(1):173-5
pubmed: 20090262
N Engl J Med. 2013 Jul 4;369(1):43-53
pubmed: 23738515
Nat Rev Cancer. 2007 Dec;7(12):899-910
pubmed: 18004397